Prioritisation board decisions 2025
We've developed a centralised approach to prioritising our guidance topics.
This ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.
Decisions will only be reviewed where there are factual errors or when significant new evidence comes to light following publication.
Stakeholders can seek clarification within 20 working days following the publication of the prioritisation board's decisions.
| Prioritisation board meeting date | Topic title | Decision | Routing decision | Rationale | Decision publication date |
|---|---|---|---|---|---|
| 20 November 2025 | NG51 Sepsis – procalcitonin tests | Prioritised | Guidelines | The Prioritisation Board agreed that guidance on the use of procalcitonin tests in sepsis would be valuable and so confirmed that the topic should be prioritised. | 27 November 2025 |
| 20 November 2025 | Diagnostic technologies for early detection of hepatocellular carcinoma in people on a surveillance programme | Not prioritised | N/A | PB agreed that the topic has potential, but there is a need for greater clarity on the use-case and the available technologies, as well as their diagnostic utility. | 27 November 2025 |
| 20 November 2025 | Digital Health Technologies (DHT’s) for the delivery of cognitive behaviour therapy (CBT) to help manage the symptoms of menopause | Prioritised | HealthTech | The Prioritisation Board agreed that the topic had the potential for benefit in terms of patient experience and acceptability, and reduced waiting times. Consequently, they agreed that the topic should be prioritised. | 27 November 2025 |
| 20 November 2025 | Developmental language disorder: diagnosis and management | Not prioritised | N/A | Prioritisation Board recognised that developmental language disorder is a significant condition that affects a large population. However, they agreed that there is unlikely to be sufficient evidence available at this time to be able to develop a useful and useable guideline. They acknowledged that the Royal College of Speech and Language Therapists has produced comprehensive resources for supporting people with DLD, and there is also a guidance document produced by the Department of Education. The Prioritisation Board agreed that the topic should not be prioritised at this time, but reconsidered if more evidence becomes available. | 27 November 2025 |
| 20 November 2025 | Prognostic tests for multiple myeloma Donor derived cell-free DNA testing in solid organ transplantation | Not prioritised | N/A | Prioritisation Board agreed that this looks to be a promising technology, but noted that currently the evidence base is limited for a number of different types of organ transplant. They noted that there are ongoing studies and agreed that the topic should. | 27 November 2025 |
| 3 November 2025 | Radiology stents: Endovascular aneurysm repair (EVAR) for abdominal aortic aneurysm | Not prioritised | N/A | Prioritisation Board recognised that there are ongoing trials of this technology and so felt that now would not be the best time to address it as a LSA. | 19 November 2025 |
| 3 November 2025 | Digital health technologies for monitoring people discharged following cirrhotic decompensation | Not prioritised | N/A | Prioritisation Board agreed that there is a potential value in the technology. However, they noted that there is an ongoing trial which should inform any future assessment. Consequently, they agreed that the topic should not be prioritised now, but it will be reconsidered once additional relevant evidence has become available. | 19 November 2025 |
| 24 October 2025 | Intraocular lenses | Prioritised | HeathTech | Prioritisation Board agreed that given the significant overall costs of lenses and the variation in initial and downstream costs from the different lens materials, there would be value in undertaking a late-stage assessment of the technology. Prioritisation Board also considered whether it would be appropriate to address the topic of multifocal lenses. They agreed that this is a promising topic and one that should be revisited once ongoing trials have published. | 26 November 2025 |
| 24 October 2025 | Digital tools and pathways for early detection of adult hearing loss | Prioritised | HealthTech | Prioritisation Board agreed that the technology has potential benefits when used in a home setting for identifying individuals who would benefit from a hearing assessment and so agreed that the topic should be prioritised | 19 November 2025 |
| 24 October 2025 | AI used with MRI for prostate cancer diagnosis | Prioritised | HeathTech | Prioritisation Board agreed that this looks to be a useful technology with the potential for benefits in diagnosis and so agreed that it should be prioritised. | 26 November 2025 |
| 24 October 2025 | Short-term 2-way catheters | Not prioritised | N/A | Prioritisation Board chose not to select this as a topic to address as a late-stage assessment as they did not believe there was significant variation in practice, and the potential for both clinical benefits and cost-reduction through addressing this topic is low. The topic will be reconsidered in 2026 to consider the use of catheters in primary care and community settings. | 26 November 2025 |
| 24 October 2025 | Vitamin D and K2 for osteopenia and osteoporosis | Not prioritised | N/A | Prioritisation Board noted that the Osteoporosis guideline is being updated with a clinical question regarding the effectiveness of vitamin D. They further recognised that questions of the appropriate dosage are addressed in the British National Formulary (BNF). They agreed that there does not look to be sufficient evidence regarding the use of vitamin K2 to develop useful and useable recommendations. Consequently, they agreed that this topic should not be prioritised. | 26 November 2025 |
| 9 October 2025 | Interventions for suicide prevention | Not prioritised | N/A | Prioritisation Board recognised the importance of this topic. However, they agreed that the majority of the evidence did not appear to indicate clear benefits for any particular intervention and so felt that it would not be possible to produce useful evidence-based recommendations on this topic. They noted that there are relevant recommendations in NICE’s guidelines for people with specific mental health conditions | 19 November 2025 |
| 9 October 2025 | Anti-embolism stockings | Not prioritised | N/A | Prioritisation Board chose not to select this as a topic to address as a late-stage assessment as they did not believe there was significant variation in practice and the potential for both clinical benefits and cost-reduction through addressing this topic is low. The topic will be reconsidered in 2026 to consider the use of anti-embolism stockings in the community setting. | 19 November 2025 |
| 9 October 2025 | Recognition of deteriorating patients in the community | Not prioritised | N/A | The Prioritisation Board recognised that there is currently a lack of good quality evidence regarding tools for monitoring deteriorating patients in the community and that consequently it would not be possible to produce useful evidence-based recommendations on this topic. | 19 November 2025 |
| 9 October 2025 | Olezarsen for treating familial chylomicronaemia syndrome | Not routed as a highly specialised technology | Technology appraisals | Prioritisation Board agreed that criteria 3 and 4 of the highly specialised technology framework were not met (see NICE-wide topic prioritisation: the manual) and that therefore the treatment should be routed to the technology appraisals programme. | 19 November 2025 |
| 9 October 2025 | Plozasiran for treating familial chylomicronaemia syndrome | Not routed as a highly specialised technology | Technology appraisals | Prioritisation Board agreed that criteria 3 and 4 of the highly specialised technology framework were not met (see NICE-wide topic prioritisation: the manual) and that therefore the treatment should be routed to the technology appraisals programme. | 19 November 2025 |
| 9 October 2025 | Digital AI tools in histopathology (breast and prostate cancer) | Prioritised | HealthTech | Prioritisation Board agreed that this appears to be a promising technology which has the potential to improve the efficiency of pathology services for this indication. They agreed that the topic should be prioritised | 19 November 2025 |
| 9 October 2025 | AI software for EEG interpretation | Prioritised | HealthTech | Prioritisation Board agreed that this appears to be a promising technology which has the potential to improve the efficiency of EEG interpretation. They agreed that the topic should be prioritised | 19 November 2025 |
| 15 September 2025 | Sleep apnoea – home fitted intra-oral device | Not prioritised | N/A | Prioritisation Board recognised that the current NICE guideline on Obstructive sleep apnoea/hypopnoea syndrome (NG202) currently includes a positive recommendation for the use of mandibular advancement splints for mild OSAHS, and consequently further assessment was not required. | 19 November 2025 |
| 15 September 2025 | Restless leg syndrome | Not prioritised | N/A | Prioritisation Board recognised that there is an existing Clinical Knowledge Summary which provides information about diagnosis and management of the condition. They also noted that restless leg syndrome management now forms part of GP training. Consequently, they agreed that this topic was not a priority for guidance. | 19 November 2025 |
| 15 September 2025 | Congenital hyperinsulinism | Not prioritised | N/A | Prioritisation Board agreed that there is insufficient evidence available regarding this rare condition in order to develop useful and useable recommendations. | 19 November 2025 |
| 15 September 2025 | Tumour treating fields for glioblastoma | Not prioritised | N/A | Prioritisation Board previously considered this topic in July 2024 where they agreed the topic should not be prioritised but reconsidered when relevant key trials have completed. They noted that some trials are ongoing, including a key trial that is likely to publish in 2026, and consequently agreed that the topic should still not be prioritised at this time, but revisited once those trials have published. | 19 November 2025 |
| 15 September 2025 | Tovorafenib for treating relapsed orrefractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people aged 6 months and over | Not prioritised as a highly specialised technology | Technology Appraisals | Prioritisation Board agreed that criteria 1 and 4 of the highly specialised technology framework were not met, and that therefore the treatment should be routed to the technology appraisals programme. | 19 November 2025 |
| 15 September 2025 | Machine perfusion devices for lung transplants | Prioritised | Healthtech | Prioritisation Board agreed that this looked to be a promising technology that addresses an unmet need in the system. Consequently, they agreed that the topic should be prioritised. | 19 November 2025 |
| 15 September 2025 | Surgical mesh for ventral hernias | Prioritised | Healthtech | Prioritisation Board agreed that given the range of different mesh products available, there would be value in addressing this topic. Consequently, they agreed that the topic should be prioritised. | 19 November 2025 |
| 15 September 2025 | Digital hearing aids | Prioritised | Healthtech | Prioritisation Board agreed that given the range of different devices available, and the depth of the evidence base for this topic there would be value in NICE addressing it. Consequently, they agreed that the topic should be prioritised | 19 November 2025 |
| 15 September 2025 | Digital hearing aids | Prioritised | HealthTech | Prioritisation Board agreed that given the range of different devices available, and the depth of the evidence base for this topic there would be value in NICE addressing it. Consequently, they agreed that the topic should be prioritised. | 6 October 2025 |
| 15 September 2025 | Surgical mesh for ventral hernias | Prioritised | HealthTech | Prioritisation Board agreed that given the range of different mesh products available, there would be value in addressing this topic. Consequently, they agreed that the topic should be prioritised. | 6 October 2025 |
| 15 September 2025 | Machine perfusion devices for lung transplants | Prioritised | HealthTech | Prioritisation Board agreed that this looked to be a promising technology that addresses an unmet need in the system. Consequently, they agreed that the topic should be prioritised. | 6 October 2025 |
| 15 September 2025 | Tumour treating fields for glioblastoma | Not prioritised | N/A | Prioritisation Board previously considered this topic in July 2024 where they agreed the topic should not be prioritised but reconsidered when relevant key trials have completed. They noted that some trials are ongoing, including a key trial that is likely to publish in 2026, and consequently agreed that the topic should still not be prioritised at this time, but revisited once those trials have published. | 6 October 2025 |
| 15 September 2025 | Congenital hyperinsulinism | Not prioritised | N/A | Prioritisation Board agreed that there is insufficient evidence available regarding this rare condition in order to develop useful and useable recommendations. They noted that the topic forms part of The Generation Study and that further evidence on this topic may be available in the future. | 6 October 2025 |
| 15 September 2025 | Restless leg syndrome | Not prioritised | N/A | Prioritisation Board recognised that there is an existing Clinical Knowledge Summary which provides information about diagnosis and management of the condition. They also noted that restless leg syndrome management now forms part of GP training. Consequently, they agreed that this topic was not a priority for guidance. | 6 October 2025 |
| 15 September 2025 | Sleep apnoea – home fitted intra-oral device | Not prioritised | N/A | Prioritisation Board recognised that the current NICE guideline on Obstructive sleep apnoea/hypopnoea syndrome (NG202) currently includes a positive recommendation for the use of mandibular advancement splints for mild OSAHS, and consequently further assessment was not required. | 6 October 2025 |
| 1 September 2025 | Technologies for the rapid diagnosis of endometriosis | Prioritised | HealthTech | Prioritisation Board recognised that endometriosis is a significant condition which affects a large population and that identifying effective diagnostic tests would be valuable. Consequently, they agreed that the topic should be prioritised | 6 October 2025 |
| 1 September 2025 | Digital health technologies to support the detection of mild cognitive impairment (MCI) | Not prioritised | N/A | Prioritisation Board recognised that the topic of mild cognitive impairment (MCI) is an important one and that NICE guidance will be needed to support the system in due course. However, they noted that there is insufficient evidence regarding treatment options for people diagnosed with MCI currently, and consequently did not feel this was the best time for guidance. | 6 October 2025 |
| 1 September 2025 | Technology for preventing complications in the second stage of labour | Not prioritised | N/A | Prioritisation Board agreed that as the technology is not yet appropriately regulated, and it is unclear when regulatory approval will be granted, it should not be considered by NICE at this time. | 6 October 2025 |
| 1 September 2025 | Non-wire technologies for lesion localisation in breast cancer surgery | Not prioritised | N/A | Prioritisation Board recognised that this technology has the potential to improve care, noting that there has been widespread adoption of the technology. However, they also noted that currently there is only limited evidence for some key outcomes. They recognised that there are rapidly evolving device innovations in this space, meaning that an evaluation of the technology at this time may not be helpful. Given this and the limited evidence, they agreed that the topic should not be prioritised at this time. However, they noted that there is an ongoing study on this technology and so it may be appropriate to reconsider this topic once more evidence is available. | 6 October 2025 |
| 1 September 2025 | Integrated neighbourhood teams | Not prioritised | N/A | Prioritisation Board agreed that this topic relates to service planning, and as such is outside NICE’s remit. Consequently, they agreed that the topic should not be prioritised. It was noted that any work in this area should involve patient groups | 6 October 2025 |
| 4 August 2025 | Non-drug therapy for dysphagia following stroke | Not prioritised | N/A | Prioritisation Board recognised that there is a need for support for people who experience dysphagia after stroke. However, they agreed that there is currently insufficient evidence available regarding non-drug therapy devices to prioritise this topic. NICE will continue to monitor evidence on this topic and revisit it at a subsequent Prioritisation Board meeting if good quality evidence becomes available. | 6 October 2025 |
| 4 August 2025 | Technologies to improve the detection of endometrial cancer | Prioritised | HealthTech | Prioritisation Board agreed that the topic had the potential for benefit in terms of patient experience and acceptability, and reduced waiting times. Consequently, they agreed that the topic should be prioritised | 19 November 2025 |
| 7 July 2025 | Routine head circumference monitoring during infancy for hydrocephalus | Not prioritised | N/A | Prioritisation Board noted that guidance around head circumference measurements from birth to 4 years of age is produced by other organisations and agreed that they would be better placed to address this topic. Consequently, they agreed that the topic should not be prioritised by NICE | 6 October 2025 |
| 7 July 2025 | IPG754 Percutaneous transluminal renal sympathetic denervation for resistant hypertension | Not prioritised | N/A | Prioritisation Board recognised that a review of the guidance is planned in 2026. They noted that engagement with clinicians has not indicated the need for an earlier review. Consequently, they agreed that the topic should not be prioritised – it will be considered for update as part of the routine review process. | 21 August 2025 |
| 7 July 2025 | Technologies to support home monitoring of vision change in macular disease | Prioritised | HealthTech | Prioritisation Board agreed that the technologies have the potential for benefit in reducing unnecessary appointments and ensuring clinic access for those with the greatest need. Consequently, they agreed that the topic should be prioritised. | 21 August 2025 |
| 7 July 2025 | ID1627 Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia | Not routed as a highly specialised technology | Technology appraisals | Prioritisation Board agreed that all 4 criteria of the highly specialised technology framework were not met (see NICE-wide topic prioritisation: the manual) and that therefore the treatment should be routed to the technology appraisals programme. | 21 August 2025 |
| 7 July 2025 | ID6488 Vosoritide for treating achondroplasia for people 4 months and over | Not routed as a highly specialised technology | Technology appraisals | Prioritisation Board agreed that criteria 1,3 and 4 of the highly specialised technology framework were not met (see NICE-wide topic prioritisation: the manual) and that therefore the treatment should be routed to the technology appraisals programme. | 21 August 2025 |
| 7 July 2025 | Energy deficit crisis in suicide | Not prioritised | N/A | Prioritisation Board agreed that there was no evidence available for this topic and that it would therefore not be possible to produce useful and useable guidance. Consequently, they agreed that this topic should not be prioritised. | 21 August 2025 |
| 7 July 2025 | Congenital talipes equinovarus (clubfoot) | Not prioritised | N/A | Prioritisation Board agreed that there was only very limited evidence available on this topic. They also noted that consensus guidance has been developed by the relevant professional body. Consequently, they agreed that this topic should not be prioritised. | 21 August 2025 |
| 7 July 2025 | Sexual dysfunction in women | Not prioritised | N/A | Prioritisation Board agreed that there was limited evidence available on this topic. They also noted that an international body has produced consensus-based resources in this area. Consequently, they agreed that this topic should not be prioritised. | 21 August 2025 |
| 7 July 2025 | Paediatric feeding disorder | Not prioritised | N/A | Prioritisation Board agreed that there was limited evidence available on this topic. They also noted that given the range of potential underlying causes for paediatric feeding disorders a single guideline on this topic would be unlikely to be useful and useable. Consequently, they agreed that this topic should not be prioritised. | 21 August 2025 |
| 16 June 2025 | Next generation sequencing technologies to measure MRD in multiple myeloma, acute lymphoblastic leukaemia & chronic lymphocytic leukaemia | Not prioritised | N/A | Prioritisation Board recognised that this potentially looks to be a useful technology but agreed that currently there appears to be insufficient evidence for NICE to be able to effectively address the topic. NICE will continue to monitor this topic and may reconsider it in due course. | 21 August 2025 |
| 16 June 2025 | ID6453 Nirogacestat for treating desmoid tumours | Not routed as a highly specialised technology | Technology appraisals | Prioritisation Board agreed that criteria 1 and 4 of the highly specialised technology framework were not met (see NICE-wide topic prioritisation: the manual), and that therefore the treatment should be routed to the technology appraisals programme. | 21 August 2025 |
| 16 June 2025 | ID6484 Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years – HST routing decision | Routed as a highly specialised technology | Highly specialised technology | Prioritisation Board agreed that all four of the criteria of the highly specialised technology framework were met (see NICE-wide topic prioritisation: the manual), and that therefore the treatment should be routed to the highly specialised technology programme. | 21 August 2025 |
| 16 June 2025 | Non-drug therapy for gastro-oesophageal acid reflux disease secondary to hiatal hernia | Not prioritised | N/A | Prioritisation Board agreed that there was very limited evidence available for this topic, and that therefore it should not be prioritised. | 21 August 2025 |
| May 2025 | Digital health technologies to support the self-management of people with chronic kidney disease | Not prioritised | N/A | Prioritisation Board recognised that Health Technology Wales is currently addressing this topic and that therefore it should not be prioritised for NICE to address at this time. | 19 June 2025 |
| 19 May 2025 | Technologies for detection and monitoring of chronic kidney disease in the community | Not prioritised | N/A | Prioritisation Board did not prioritise this topic. They noted that there are two potential use-cases for the technology – for early detection, and for monitoring. Regarding early detection, they noted that the NICE guideline on Chronic kidney disease (NG203) contains comprehensive recommendations for the targeted screening of patients at risk of CKD. They did not feel that there was a clear role for point of care testing here. Regarding monitoring, the Board did not feel that there was a clear use-case for the technology which would lead to patient benefit over the existing laboratory testing approach. They agreed that further research on this topic would potentially be beneficial and will liaise with the NIHR to explore this. | 19 June 2025 |
| 19 May 2025 | Gel nail polish UK dentistry | Not prioritised | N/A | Prioritisation Board agreed that the question of whether it is appropriate for dentists to be able to wear gel nail polish is a professional standards issue and not within NICE’s remit. | 19 June 2025 |
| 19 May 2025 | Charles Bonnet syndrome | Not prioritised | N/A | Prioritisation Board agreed that the key issue relating to this topic is primarily one of awareness, with a need for relevant clinicians to be aware of the condition so that it can form part of their assessment of patients. They felt that this is primarily a training issue and consequently a topic that would be best addressed through ensuring it is included in professional training curricula. Therefore, Prioritisation Board did not prioritise this topic. | 19 June 2025 |
| 7 May 2025 | Thoracic endometriosis | Not prioritised | N/A | Prioritisation Board agreed that there is insufficient evidence available regarding this rare condition in order to develop useful and useable recommendations. It was recognised that there is European guidance on this topic and NICE will explore whether this can be cross-referred to. | 2 June 2025 |
| 7 May 2025 | Pessary care management | Not prioritised | N/A | Prioritisation Board agreed that existing NICE guidance on Urinary incontinence and pelvic organ prolapse (NG123) and Pelvic floor dysfunction (NG210) contain recommendations regarding the use of pessaries and that therefore this topic was not a priority to address. | 2 June 2025 |
| 7 May 2025 | Hyperinsulinism in adults | Not prioritised | N/A | Prioritisation Board agreed that there is insufficient evidence available regarding this rare condition in order to develop useful and useable recommendations. | 2 June 2025 |
| 7 May 2025 | Chronic rhinosinusitis with nasal polyps | Not prioritised | N/A | Prioritisation Board recognised that there are ongoing technology appraisals for biological treatments for this condition. They also noted that there is currently only limited evidence available regarding surgical options and consequently agreed that the topic should not be prioritised. | 2 June 2025 |
| 7 May 2025 | Non-diabetic foot ulcers | Not prioritised | N/A | Prioritisation Board recognised that there are existing National Wound Care Strategy Programme recommendations regarding foot ulcers. They also noted that the Scottish Intercollegiate Guidelines Network (SIGN) has indicated that it will be developing guidance regarding lower limb ulcers. Consequently, they agreed that there would not be sufficient value in NICE developing additional guidance in this area and confirmed that the topic should not be prioritised. | 2 June 2025 |
| 7 May 2025 | Childhood hearing loss | Not prioritised | N/A | Prioritisation Board agreed that there is a lack of good quality evidence available on this topic. They also recognised that NICE has existing guidance on Otitis media with effusion in under 12s (NG233) which is a major cause of hearing loss in the paediatric population. Consequently, they agreed the topic should not be prioritised. | 2 June 2025 |
| 7 May 2025 | Cochlear implants for single-sided hearing loss | Not prioritised | N/A | Prioritisation Board agreed that given existing recommendations regarding cochlear implants for bilateral hearing loss in TA566, the issue of implants for single-sided hearing loss was not a priority for the system and consequently did not prioritise the topic. | 2 June 2025 |
| 7 May 2025 | Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments (ID6388) | Not prioritised as a highly specialised technology | Technology appraisals | Prioritisation Board agreed that criteria 1,2 and 4 of the highly specialised technology framework were not met (see NICE-wide topic prioritisation: the manual) and that therefore the treatment should be routed to the technology appraisals programme. | 2 June 2025 |
| 9 April 2025 | Prolonged grief disorder | Not prioritised | N/A | Update 13/11/25 Prioritisation Board originally prioritised this topic in April 2025. However, following a review, the Board decided that the topic should be deprioritised. They noted that the evidence for this topic primarily relates to a single intervention and so there was uncertainty that producing guidance on the topic would add value. The topic will be reconsidered for prioritisation in 2026. | 19 November 2025 |
| 9 April 2025 | Technologies for sampling abnormal cells in the oesophagus | Prioritised | HealthTech | Prioritisation Board recognised that the use of the technology for the surveillance of people with diagnosed Barrett’s oesophagus has the potential for reducing unnecessary endoscopies, thereby saving costs for the NHS and reducing waiting times for endoscopies overall. | 30 April 2025 |
| 9 April 2025 | Technologies to support pre-operative and post-operative rehabilitation for patients undergoing hip or knee surgery | Prioritised | HealthTech | Prioritisation Board recognised that the technology in this area has the potential to improve care and reduce waiting times for both pre-operative and post-operative rehabilitation. Consequently, they prioritised this topic. | 30 April 2025 |
| 9 April 2025 | Finger oximetry thresholds | Not prioritised | N/A | Prioritisation Board noted that the recommendations regarding oximeters across NICE’s guideline portfolio contain information regarding the accuracy, proper placement of monitors and warnings about the potential for overestimation in people with darker skin tones. Consequently, they did not feel that updates to the recommendations were required and the topic was not prioritised. They recognised that there is a technology for in-ear oxygen measurement that has been selected as part of the Innovative Devices Access Pathway (IDAP) programme which will be assessed through that process. | 30 April 2025 |
| 9 April 2025 | Chemical adherence testing for apparent resistant hypertension | Not prioritised | N/A | The Prioritisation Board noted that there was only very limited evidence available on this topic and that consequently the topic should not be prioritised. NICE will engage with the NIHR to explore whether additional evidence can be generated on this topic. | 30 April 2025 |
| 26 March 2025 | Cataracts – intraocular lens selection (NG77) | Prioritised | Guidelines for initial assessment | Prioritisation Board recognised that there is good quality evidence on this topic, with recommendations regarding particular types of intraocular lens likely to lead to reduced rates of posterior capsule opacification – a common complication after cataract surgery. | 30 April 2025 |
| 26 March 2025 | Artificial Intelligence assisted Echocardiography to support diagnosis of heart failure | Prioritised | HealthTech | Prioritisation Board recognised the potential system benefits of AI-enhanced echocardiogram in leading to improved accuracy of diagnosis and reduced waiting times. Consequently, they agreed this topic should be prioritised. | 30 April 2025 |
| 26 March 2025 | Digital technologies that deliver CBT interventions for insomnia and insomnia symptoms (Disordered sleep) | Prioritised | HealthTech | Prioritisation Board recognised that chronic insomnia impacts on a large population and that digital technologies have the potential to address the unmet need of in-person CBT provision. They recognised that a range of different digital technologies are available and agreed that there would be value in a multi-tech assessment of these products. Consequently, they agreed to prioritise this topic. | 30 April 2025 |
| 26 March 2025 | Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over (ID6497) | Not prioritised as a highly specialised technology | Technology appraisals | Prioritisation Board agreed that criteria 1,3 and 4 of the highly specialised technology criteria were not met (see appendix 1 of NICE-wide topic prioritisation: the manual). Consequently, it was agreed that the treatment should be routed to the technology appraisals programme. | 30 April 2025 |
| 26 March 2025 | Tonsillectomy for recurrent tonsilitis in adults | Not prioritised | N/A | Prioritisation Board recognised that there is existing guidance from the Academy of Medical Royal Colleges regarding tonsillectomy for recurrent tonsilitis. This guidance is aligned with advice for specialist assessment detailed in the clinical knowledge summary on sore throat. Consequently, they agreed that this topic should not be prioritised. | 30 April 2025 |
| 26 February 2025 | Blood transfusion (NG24) – tranexamic acid | Prioritised | Centre for Guidelines | Prioritisation Board recognised that there is good quality evidence to support expanding the population who could receive tranexamic acid during surgery. There also appear to be potential resource savings for the NHS. | 21 March 2025 |
| 26 February 2025 | Tics and Tourette’s syndrome | Not prioritised | N/A | Prioritisation Board agreed this is a complex topic that overlaps considerably with other conditions. Many of the challenges relate to service provision, where NICE guidance is likely to have limited impact. It was, however, recognised that there could be value in developing a clinical knowledge summary on this topic, and NICE will explore this possibility further. | 21 March 2025 |
| 26 February 2025 | Digital technologies to support people with severe mental illness in community settings | Not prioritised | N/A | Prioritisation Board agreed that there is a lack of evidence in this area, and a lack of certainty regarding the potential benefits of any technology to allow NICE to develop guidance on this topic. It is an area that may benefit from additional research and NICE will liaise with system partners to explore this need for evidence generation. | 21 March 2025 |
| 26 February 2025 | Machine perfusion devices for preservation of solid livers for transplant | Prioritised | HealthTech | Prioritisation Board agreed that this looked to be a promising technology that addresses an unmet need in the system. Consequently, they agreed that the topic should be prioritised. | 21 March 2025 |
| 24 January 2025 | Digital stethoscope for point-of-care detection of heart murmurs/arrhythmia | Not prioritised | N/A | Prioritisation Board recognised that this is an important topic that will likely be of value to the system. However, they noted that there is an ongoing trial of this technology which is due to publish its results in December 2025. The topic will be reconsidered once those results have published. | 21 February 2025 |
| 24 January 2025 | Tuberculosis | Not prioritised | N/A | Prioritisation Board recognised that this is an important topic but that other agencies may be better placed to develop guidance on this topic. NICE will liaise with the UK Health Security Agency (UKHSA) to explore options as to how guidance should be developed on this topic. | 21 February 2025 |
| 24 January 2025 | GP identification and management of life-threatening emergencies | Not prioritised | N/A | Prioritisation Board agreed that this topic is primarily related to training and professional development and that consequently NICE guidance on this topic would not be appropriate. | 21 February 2025 |
| 24 January 2025 | Plantar fibromatosis aka Ledderhose | Not prioritised | N/A | Prioritisation Board agreed that there is very limited evidence available regarding this condition, and that there would not be value in producing a guideline. It was noted that there is an existing Clinical Knowledge Summary regarding Dupuytren’s disease and so it will be explored whether this could be expanded to also cover plantar fibromatosis. | 21 February 2025 |
| 24 January 2025 | Ketamine uropathy | Not prioritised | N/A | Prioritisation Board noted that NICE has produced guidance regarding drug misuse prevention, and that there is a consensus statement from the British Association of Urological Surgeons on this topic. Consequently, they agreed that this topic should not be prioritised. | 21 February 2025 |
| 24 January 2025 | Pain management in people receiving long term end of life care | Not prioritised | N/A | Prioritisation Board noted that NICE has produced a range of guidance regarding pain management, some of which will be relevant to this population. It was agreed that NICE will not develop guidance in this area, but will explore whether a Clinical Knowledge Summary can be produced regarding pain management in non-cancer palliative care. | 21 February 2025 |